RARE (Ultragenyx Pharma) Forward P/E Multiple

Graphic logo of ultragenyx.com (RARE)

Ultragenyx Pharmaceutical (RARE) maintains an impeccable reputation in the treatment of rare pathologies, as evidenced by the dynamics of the company's forward P/E, where the 217.30 level serves as a critical benchmark for investment security. The high cost of cryogenic delivery for life-saving drugs complicates logistics and increases expenses. Business efficiency is sustained through flexible outsourcing of early-stage development via a network of external laboratories.

RARE - ultragenyx.com Forward Price to Earnings Multiple over the range 07/04/2022 - 11/18/2026

Ultragenyx (RARE) - metric breakdowns and financial figures

- stock value and consensus price forecast:
Analysis of all company metrics:Ultragenyx Pharmaceutical RARE
Signature product of ultragenyx.com

To minimize investment risks, it is critical to evaluate share value through the lens of expected earnings, which is particularly relevant for Ultragenyx Pharmaceutical (RARE) given its gene therapy strategies and M&A potential. By analyzing the company's forward P/E fluctuations, an investor compares the current price with future earnings to determine the extent to which the market has priced in the success of innovative DNA modifications and partnership synergies.

Who Ultragenyx Pharmaceutical competes with

Projected Price to Earnings TEM (Tempus AI, Inc)|Qiagen Group (QGEN) - Forward Price to Earnings Multiple|Future Price to Earnings ionispharma.com IONS|Market Cap to Projected Earnings Repligen Corporation (RGEN)|RNA: Projected Price to Earnings|Future Price to Earnings Multiple CRSP (CRISPR Therapeutics Corp)|WGS: Forward P/E Multiple|Beam Therapeutics Corp - Future Price to Earnings Multiple|Projected Price to Earnings SRPT|twistbioscience.com (TWST) - Market Cap to Projected Earnings|Forward P/E Multiple TXG|NTLA (Intellia) - Future Price to Earnings Multiple|Future Price to Earnings Stoke STOK|BioLife (BLFS) - Projected Price to Earnings Ratio|wavelifesciences.com - Forward P/E Multiple|Price to Expected Earnings Ratio MAZE|SION: Forward P/E Multiple|PRME - Market Cap to Projected Earnings|Projected Price to Earnings TSHA|QURE - Forward Price to Earnings Multiple|Forward P/E Multiple MGTX|Market Cap to Projected Earnings regenxbio.com|Forward P/E Multiple SLDB (Solid Biosciences Inc)|OCGN: Price to Future Earnings Ratio|PACB - Future Price to Earnings|Benitec (BNTC) - Projected Price to Earnings|DSGN: Forward P/E Multiple|RCKT: Market Cap to Future Earnings Ratio|FDMT (4D Molecular Therapeutics, Inc.) - Forward P/E Multiple|lexeotx.com (LXEO) - Market Cap to Projected Earnings|Forward P/E Multiple KRRO|Projected Price to Earnings Editas Medicine, Inc. EDIT|Future Price to Earnings silence-therapeutics.com SLN|PRQR: Price to Future Earnings Ratio|CDXS - Future Price to Earnings|Market Cap to Projected Earnings Sangamo Therapeutics, Inc. SGMO|NAUT (nautilus.bio) - Projected Price to Earnings|Projected Price to Earnings Ratio Metagenomi, Inc. (MGX)|Projected Price to Earnings DTIL|Price to Future Earnings Ratio GBIO (generationbio.com)|Future Price to Earnings Boundless Bio, Inc (BOLD)|Forward P/E Multiple Exicure Inc. (XCUR)|Imunon, Inc. - Projected Price to Earnings|PHIO: Price to Future Earnings Ratio|MBIO - Future Price to Earnings|Price to Expected Earnings Ratio RNAZ|Bionano Genomics, Inc. (BNGO) - Future Price to Earnings|Applied DNA Sciences, Inc. (APDN) - Forward P/E Multiple|BLUE (bluebirdbio.com) - Forward P/E Multiple|Price to Future Earnings Ratio IPA (ImmunoPrecise Antibodies)|Forward P/E Multiple OMGA|Projected Price to Earnings Singular Genomics Systems OMIC|Forward P/E Multiple RGLS (regulusrx.com)|Syros Pharmaceuticals Inc. (SYRS) - Projected Price to Earnings Ratio|TBIO: Projected Price to Earnings|Future Price to Earnings Multiple TCON (TRACON)|UBX: Forward P/E Multiple